Cart
sales@molnova.com
4-Chloro-2-(trifluoroacetyl)aniline hydrochloride
CAS No. 173676-59-0
4-Chloro-2-(trifluoroacetyl)aniline hydrochloride( —— )
Catalog No. M20868 CAS No. 173676-59-0
4-Chloro-2-(trifluoroacetyl)aniline hydrochloride is an inhibitor of HIV-1 RT (HIV reverse transcriptase) .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 29 | In Stock |
|
| 25MG | 52 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 122 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 303 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4-Chloro-2-(trifluoroacetyl)aniline hydrochloride
-
NoteResearch use only, not for human use.
-
Brief Description4-Chloro-2-(trifluoroacetyl)aniline hydrochloride is an inhibitor of HIV-1 RT (HIV reverse transcriptase) .
-
Description4-Chloro-2-(trifluoroacetyl)aniline hydrochloride is an inhibitor of HIV-1 RT (HIV reverse transcriptase) .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV-1 RT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number173676-59-0
-
Formula Weight260.04
-
Molecular FormulaC8H6Cl2F3NO
-
Purity>98% (HPLC)
-
SolubilityDMSO:52mg/mL(199.97mM)
-
SMILESCl.Nc1ccc(Cl)cc1C(=O)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Peptide T
Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.
-
Abacavir sulfate
A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS.
-
Opaviraline
Opaviraline (GW-420867X) is a potent reverse transcriptase inhibitor that inhibits Human immunodeficiency virus 1 and has the potential to treat HIV infection.
